Axsome breaks new ground in Alzheimer's with Auvelity OK
Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.
Parexel buys Vitrana to boost patient safety toolkit
Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum.
GLP-1s drive Lilly's Q1, but it's reticent on oral launch
Investors are itching for news on the rollout of Lilly's oral weight-loss drug Foundayo, but there's little information in its first-quarter update.
Avalyn seeks $300m from its IPO
Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.
Teva makes its first M&A play in years, buying Emalex
Teva has made its first pipeline-building acquisition in almost a decade, buying Tourette syndrome drug developer Emalex for up to $900m.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CR...
Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions
PHARMAP 2026: From Vendors to Strategic Partners
Strategic Partnerships at PHARMAP 2026 – Big Pharma’s Shift Toward CDMOs and CMOs
WOMA 2026: Steering the Future of Pharma Strategy
The WOMA Forum is not merely a conference. It's a convergence point for decision-makers